DOCSLIB.ORG

Discovery Consists of Seeing What Everybody Has Seen, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Discovery consists of seeing “ “ what everybody has seen, and thinking what nobody has thought. Albert SZENT-GYORGYI, 1937 Nobel Prize for Medicine 1 ADMINISTRATIVE STRUCTURE The administrative structure of the Institute is composed of an Institute Administrative Coordinator, a Clinical Research Unit and the Logistics and Accounts Unit. This structure ensures a transversal support to all Research Groups. Institutes Administrative Coordinator (CAI): Michel Van Hassel Clinical Research Unit: Regulatory Affairs, Quality, Contract-Budget Analysis of Clinical Trials Clémentine Janssens Valérie Buchet Salvatore Livolsi Marie Masson Dominique Van Ophem Logistics and Accounts Unit: Maimouna Elmjouzi MBLG/CTMA Myriam Goosse-Roblain MIRO Eric Legrand CHEX Cyril Mougin FATH/RUMA Michel Notteghem CARD/EDIN Dora Ourives Sereno GYNE/PEDI/GAEN Nadtha Panin LTAP IREC General Address: Avenue Hippocrate, 55 bte B1.55.02 1200 Woluwe-Saint-Lambert Internet Address: http://www.uclouvain.be/irec.html 2 The Institute brings together different research groups who work to improve our understanding of disease mechanisms, as well as to discover and/or develop new therapeutic strategies. Basic research joins clinical research in an enriching environment where clinical scientists and basic researchers can exchange their experiences and work on common projects. Our focus is thus clearly on translational research. Research at our Institute covers a wide range of biomedical problems and is mostly organized in an organ or system specific manner. The Institute is composed of 21 research groups working in close collaboration with the Cliniques universitaires Saint- Luc, in Brussels, and Mont-Godinne, in Yvoir. The Institute brings together more than 500 researchers and PhD students of different horizons and provides logistical support for both basic and clinical research. Jean-Luc Balligand IREC President 3 RESEARCH EXPENDITURES AT INSTITUTIONAL LEVEL 2010-2014(K€): 4 NEW RESEARCH AGREEMENTS AND CONTRACTS CONCLUDED 2011-2015: 5 RESEARCH GROUPS Cardiovascular Research (CARD) 07 Computer Assisted Robotic Surgery (CARS) 24 Experimental Surgery and Transplantation (CHEX) 36 Endocrinology, Diabetes and Nutrition (EDIN) 46 Epidemiology and biostatistics (EPID) 56 Pharmacology and Therapeutics (FATH) 62 Hepato-Gastro-Enterology (GAEN) 77 Gynecology (GYNE) 88 Medical Imaging Research (IMAG) 100 Louvain Centre for Toxicology and Applied Pharmacology (LTAP) 124 Medical Microbiology (MBLG) 134 Molecular Imaging, Radiotherapy and Oncology (MIRO) 146 Morphology (MORF) 160 Nephrology (NEFR) 174 Pediatrics (PEDI) 178 Pneumology, ENT and Dermatology (PNEU) 190 Rheumatic Pathology (RUMA) 196 Centre for Applied Molecular Technologies (CTMA) 202 6 EXPERIMENTAL RESEARCH GROUP CLINICAL RESEARCH GROUP R Magali BALTEAU, Postdoctoral Fellow R Valerie LACROIX, PhD Student R Diego CASTANARES, Postdoctoral Fellow R Florence MAILLEUX, PhD Student R Evangelos P DASKALOPOULOS, Postdoctoral Fellow R Frederick MAES, PhD Student R Yeliz ANGIN, Postdoctoral Fellow R Julie MELCHIOR, PhD student R Gauthier-Thibaut NOPPE, PhD Student R R Jean-Louis Christophe BEAULOYE Mihaela AMZULESCU, PhD student Matteo PETTINARI, PhD Student VANOVERSCHELDE MD, PhD R Julien AUQUIER, PhD student R Sophie PIERARD, PhD Student MD, PhD R Jamila BOULIF, PhD student R Edith RENGUET, PhD Student R Christophe de MEESTER, PhD student R Nawal REZZOUG, PhD Student R Fabian DEMEURE, PhD Student R Clothilde ROY, PhD Student R Cécile DUFEYS, PhD Student R Allison SLIMAIN, PhD Student R Shakeel KAUTBALLY, PhD student R Stéphanie SELDRIUM , PhD Student R Sophie LEPROPRE, PhD Student R Aurélie TIMMERMANS, PhD Student R Olivier VAN CAENEGEM, PhD Student Luc BERTRAND Sandrine HORMAN PhD PhD R Anne VANSTEENBERGEN, PhD Student R Patricia BUCHLIN, Research Scientist R Audrey GINION, Research Scientist R Xavier HAVAUX, Research Scientist R Nicolas MARQUET, Technician R Delphine THIBOU, Animal Technician Bernhard GERBER Agnès PASQUET A-Catherine POULEUR David VANCRAEYNEST MD, PhD MD, PhD MD, PhD MD, PhD Alexandre PERSU Gébrine EL KHOURY Parla ASTARCI Philippe NOIRHOMME Laurent DE Kerchove Joëlle KEFER Jean-Benoît LE POLAIN de WarouX MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD MD, PhD CARDIOVASCULAR RESEARCH (CARD) The importance of cardiovascular disease in terms of public health is well established. Cardiovascular diseases, mainly secondary to atherosclerosis, are responsible for about 50% of deaths in industrialized countries. Since it is not possible to study all aspects of the cardiovascular disease, our research unit has determined its main lines of investigation based on its expertise and know-how and also on the clinical applicability of the scientific topics, which are addressed. Our research focus on 4 main axes : 1. Research on the role of intracellular signalling in cardiovascular diseases like type 2 diabetes, cardiac hypertrophy and heart failure. 2.Research on valvular diseases. 3.Research in cardiac imaging. 4.Research on platelet signaling and metabolism. These 4 main research areas are highly interconnected, integrating both clinical and basic research. Our unit has developed a number of skills ranging from molecular and cell biology to biochemistry and population studies. Our researchers bring their own expertise to the entire research program. 7 EXPERIMENTAL RESEARCH GROUP Role of fibroblastic AMPKα1 in We next examined mechanisms responsible for left ventricular remodeling after the increased LV remodeling in Per-KO mice, fo- cusing on Connexin 43 (Cx43) and lysyl oxidase myocardial infarction (Lox), two proteins critically involved in many aspects of cardiovascular physiology. We found Cécile Dufeys, Evangelos P Daskalopoulos, that Cx43 and Lysyl oxidase (Lox) expression Nicolas Marquet, Christophe Beauloye, were drastically reduced in CF isolated from in- Sandrine Horman farcted Per-KO hearts. This result was confirmed in vitro, in human CF transfected with a specific The term “ventricular remodelling” refers to siRNA targeting AMPKα1. Interestingly, the pro- changes in left ventricle (LV) structure in res- tein levels were decreased at a higher extent than CARDIOVASCULAR RESEARCH CARDIOVASCULAR ponse to physiological and pathological haemo- the mRNA levels, indicating that post-transcrip- dynamic stress. Data of our group strongly sup- tional mechanisms were probably involved in the port that AMP-activated protein kinase (AMPK) AMPKα1-dependent Cx43 and Lox regulation. controls key mechanisms involved in adverse LV remodelling, such as cardiomyocytes hyper- In conclusion, we report that the deletion of trophy and fibrosis. However, a crucial question AMPKα1, specifically in CF, promotes LV dilata- remains unsolved. It is not known which cardiac tion after MI. We identified Cx43 and Lox as two cell types play the predominant role in the pro- new downstream targets of AMPKα1, and likely tective effect of AMPK. This is due to the fact mediators of its function in the control of CF bio- that most of the studies performed on animal logy and LV remodeling (Figure 1). The obtained models used for genetic invalidation of AMPK data support the emergent notion that therapeu- are whole-body knockout (KO) of AMPK catalytic tic modulation of CF function may represent a subunits. The generation of tissue-specific and novel approach to the prevention and/or treat- conditional KO animals where AMPK is selecti- ment of heart failure. ¢ vely invalidated in specific cardiac cell types will allow to better determine the relative impact of each AMPK action on cardiac pathology. The hypothesis that drives this project, and which is strongly supported by our previous and current studies, is that AMPKα1 from cardiac fibroblasts (CF) is a central player in the func- tional and structural adaptation of the heart in response to cardiac injury. We therefore generated a mouse strain (Perios- tin-Cre+/AMPKα1fl/fl) in which AMPKα1 can be specifically invalidated in CF in response to myo- cardial infarction (MI), induced by the permanent ligation of the left anterior coronary artery (Per- Figure 1 : Role of AMPK in the ischaemic and post-is- KO). We show that infarct size was not different chaemic heart. AMPK prevents the progression of adverse LV remodeling (1) by increasing the survival of cardiomyo- between WT and Per-KO mice. At basal state, cytes during ischemia and the post-ischemic period, (2) WT and Per-KO hearts were comparable, but 4 by contributing to the formation of a mature collagen scar weeks after MI, Per-KO mice had a greater in- through the control of fibroblastic properties via a mecha- crease in end-diastolic and end-systolic dimen- nism involving regulation of Cx43 and Lox. sions in comparison to WT, reflecting an accele- rated dilatative remodeling. 8 Elucidation of the molecular mechanisms involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake Julien Auquier, Audrey Ginion, Edith Renguet, Christophe Beauloye, Sandrine Horman, Luc Bertrand Diabetic hearts are known to be more suscep- tible to myocardial infarction. Insulin resistance and its consequence, the impairment of glucose Figure 2 : Molecular signalling involved in the regulation of cardiac glucose uptake by insulin and AMPK. Insulin uptake, are partially responsible for this vulne- binds to its receptor (IR) and activates PKB via the insulin rability. In previous work, we discovered that receptor substrate 1 (IRS-1)/phosphatidylinositol-3 kinase RESEARCH CARDIOVASCULAR pharmacological activation of AMPK, including (PI3K) pathway.
Recommended publications
  • Palaeolithic Bone Retouchers from Belgium: a Preliminary­ Overview of the Recent Research Through Historic and Recently Excavated Bone Collections

    Palaeolithic Bone Retouchers from Belgium: a Preliminary­ Overview of the Recent Research Through Historic and Recently Excavated Bone Collections

    GRÉGORY ABRAMS PALAEOLITHIC BONE RETOUCHERS FROM BELGIUM: A PRE LIMINARY OVERVIEW OF THE RECENT RESEARCH THROUGH HISTORIC AND RECENTLY EXCAVATED BONE COLLECTIONS Abstract Since the first half of the 19th century, Belgium has provided a multitude of sites dating back to the Palaeo- lithic. These discoveries have contributed to the definition of the Palaeolithic and to the understanding of prehistoric people. This long tradition of research has resulted in the collection of thousands of bones that are increasingly the subject of extensive analysis, including the study of bone retouchers. At present, this re- search has identified 535 retouchers in various Belgian repositories. The tools come from different sites with highly variable and incomplete contextual information depending on their excavation history (e.g., Trou du Diable and the Caves of Goyet). In contrast, unit 5 of Scladina Cave constitutes a well-defined assemblage. Bones with fresh fracture patterns provide interesting technological data, such as a refitted cave bear femo- ral shaft that includes four retouchers. The use of cave bear bones for producing tools at Scladina Cave as well as retouchers made from Neanderthal remains from the 3rd Cave of Goyet gives rise to questions about the possible symbolic meanings attributed to particular species. Keywords Belgium; Middle Palaeolithic; Retouchers; Neanderthals; Cave bear; Refitting Introduction Belgian Palaeolithic research has its roots deep in ness of cave sites was such that most were explored the first half of the 19th century with the work of during the 19th century. Philippe-Charles Schmerling, who found the first Since the beginning of research into Belgian Neander thal remains in Engis Cave in the early prehistory, archaeologists have focused their atten- 1830s.
  • Copyright by Ernesto Lopez 2015

    Copyright by Ernesto Lopez 2015

    Copyright by Ernesto Lopez 2015 The Dissertation Committee for Ernesto Lopez Certifies that this is the approved version of the following dissertation: The role of arginine vasopressin receptor 2 in microvascular hyperpermeability during severe sepsis and septic shock Committee: Perenlei Enkhbaatar, M.D., Ph.D. Supervisor or Mentor, Chair Jose M. Barral M.D., Ph.D. Donald S. Prough, M.D. Robert A. Cox, Ph.D. Jae-Woo Lee, M.D. _______________________________ David W. Niesel, PhD. Dean, Graduate School The role of arginine vasopressin receptor 2 in microvascular hyperpermeability during severe sepsis and septic shock by Ernesto Lopez, M.D. Dissertation Presented to the Faculty of the Graduate School of The University of Texas Medical Branch in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas Medical Branch 2015 Acknowledgements First I would like to gratefully thank my mentor, Dr. Enkhbaatar for his dedication and support and for giving me the opportunity to work in his lab as a graduate student. Dr. Enkhbaatar helped me to improve my scientific and professional skills with great attention. I had a true opportunity to be exposed to every aspect of the biomedical sciences. Moreover, I would like to express my gratitude to the members of my dissertation committee Dr. Prough, Dr. Cox, Dr. Barral and Dr. Lee as well as Dr. Hawkins, Dr. Herndon, Dr. Rojas and Jacob MS, for all the critiques and ideas that certainly enhanced this project. I would also like to thank to all current and past members of the translational intensive care unit (TICU) for their enormous support and professionalism in completing this project; John Salsbury, Christina Nelson, Ashley Smith, Timothy Walker, Mackenzie Gallegos, Jisoo Kim, Uma Nwikoro, Ryan Scott, Jeffrey Jinkins, Lesia Tower, Cindy Moncebaiz, Cindy Hallum, Lindsey Willis, Paul Walden, Randi Bolding, Jameisha Lee, Mengyi Ye, as well as Drs.
  • Supplementary TABLE 1

    Supplementary TABLE 1

    Note: This is Online Supplementary Document 1 of Koster W, Ndione AG, Adama M, et al. An oral history of medical laboratory development in francophone West African countries. Afr J Lab Med. 2021;10(1), a1157. https://doi.org/10.4102/ajlm.v10i1.1157 Supplementary TABLE 1: Physical places where literature was accessed [BR1] Country/city Place where documents were accessed Burkina Faso, Unité de Formation et de Recherche en sciences de la santé (UFR/SDS) de Ouagadougou l’université Ouaga 1 Professeur Joseph Ki Zerbo Centre National de Recherche Scientifique et Technologique (CNRST) Ecole National de Santé Publique (ENSP), Direction générale Union Monétaire des États de l’Afrique de l’Ouest (UEMOA) Institut de Recherche en Développement (IRD) Organisation mondiale de la Santé (OMS) au Burkina Faso Burkina Faso, Ecole National de Santé Publique (ENSP), Direction régionale Bobo Dioulasso Centre Muraz L’Organisation Ouest Africaine de la Santé (OAAS) Mali Institut National de Recherche en Santé Publique (INRSP) Bamako Bibliothèque nationale Archives nationales Centre National d’Appui à la lutte contre la Maladie (CNAM) ex-Institut Marchoux Faculté de Médecine et d’Odonto- Stomatologie et Faculté de Pharmacie Direction Nationale de la Santé (DNS) Direction de la Pharmacie et du Médicament (DPM) Pharmacie Populaire du Mali (PPM) Institut National de Formation en Sciences de la Santé (INFSS) Inspection de la santé Organisation mondiale de la Santé (OMS) à Bamako Senegal Bibliothèque universitaire de Dakar Dakar Assemblée Nationale du Sénégal Agence
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • Advanced Non-Small Cell Lung Cancer: Retrospective Study Of

    Advanced Non-Small Cell Lung Cancer: Retrospective Study Of

    i e r Sc c nce e a c n an d C R f Journal of Cancer Science and e o s l e a a n r r c EL-Hadaad et al., J Can Sci Res 2017, 3:S1 h u o J Research DOI: 10.4172/2576-1447.1000S1-011 ISSN: 2576-1447 Research Article Open Access Advanced Non-Small Cell Lung Cancer: Retrospective Study of Prognostic Factors Hend A EL-Hadaad1*, Yasser M Saleh1, Hanan A Wahba1 and Magda A Ahmad2 1Department of Clinical Oncology& Nuclear Medicine, Mansoura University, Egypt 2Chest Medicine department, Mansoura University, Egypt *Corresponding author: Dr. Hend Ahmed El-Hadaad, MD, Faculty of medicine, University of Mansoura, Egypt, Tel: +20124272772; E-mail: [email protected] Received date: March 09, 2017; Accepted date: March 28, 2017; Published date: March 31, 2017 Copyright: © 2017 EL-Hadaad HA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: The objective of the study is to investigate and improve our understanding of the impact of several potential prognostic factors on overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). Methods: Records of patients with advanced NSCLC (stage IIIB, IV) received first-line chemotherapy were reviewed. Age, gender, Eastern Cooperative Oncology Group performance status (ECOGPS), stage, histologic type, smoking status, leucocytic count, type of chemotherapy, albumin and hemoglobin level were evaluated for their prognostic significance in multivariate analysis.
  • Assessing Relationships Between Human Adaptive Responses and Ecology Via Eco-Cultural Niche Modeling William E

    Assessing Relationships Between Human Adaptive Responses and Ecology Via Eco-Cultural Niche Modeling William E

    Assessing relationships between human adaptive responses and ecology via eco-cultural niche modeling William E. Banks To cite this version: William E. Banks. Assessing relationships between human adaptive responses and ecology via eco- cultural niche modeling. Archaeology and Prehistory. Universite Bordeaux 1, 2013. hal-01840898 HAL Id: hal-01840898 https://hal.archives-ouvertes.fr/hal-01840898 Submitted on 11 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Thèse d'Habilitation à Diriger des Recherches Université de Bordeaux 1 William E. BANKS UMR 5199 PACEA – De la Préhistoire à l'Actuel : Culture, Environnement et Anthropologie Assessing Relationships between Human Adaptive Responses and Ecology via Eco-Cultural Niche Modeling Soutenue le 14 novembre 2013 devant un jury composé de: Michel CRUCIFIX, Chargé de Cours à l'Université catholique de Louvain, Belgique Francesco D'ERRICO, Directeur de Recherche au CRNS, Talence Jacques JAUBERT, Professeur à l'Université de Bordeaux 1, Talence Rémy PETIT, Directeur de Recherche à l'INRA, Cestas Pierre SEPULCHRE, Chargé de Recherche au CNRS, Gif-sur-Yvette Jean-Denis VIGNE, Directeur de Recherche au CNRS, Paris Table of Contents Summary of Past Research Introduction ..................................................................................................................
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1

    207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1

    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
  • Medical Laboratory and Diagnosis Volume 7 Number 6 December 2016 ISSN 2141-2618

    Medical Laboratory and Diagnosis Volume 7 Number 6 December 2016 ISSN 2141-2618

    Journal of Medical Laboratory and Diagnosis Volume 7 Number 6 December 2016 ISSN 2141-2618 ABOUT JMLD Journal of Medical Laboratory and Diagnosis (JMLD) is published monthly (one volume per year) by Academic Journals. Journal of Medical Laboratory and Diagnosis (JMLD) provides rapid publication (monthly) of articles in all areas of the subject such as Parasitism, Helminthology, Cloning vector, retroviral integration, Genetic markers etc. Contact Us Editorial Office: [email protected] Help Desk: [email protected] Website: http://www.academicjournals.org/journal/JMLD Submit manuscript online http://ms.academicjournals.me/ Editors Dr. Ratna Chakrabarti Dr. Rokkam Madhavi Department of Molecular Biology and Microbiology, Andhra University University of Central Florida, Visakhapatnam - 530003 Biomolecular Research Annex, Andhra Pradesh 12722 Research Parkway, India. Orlando, USA. Dr. Mukabana Wolfgang Richard School of Biological Sciences Dr. Rajni Kant University of Nairobi Scientist D (ADG), P.O. Box 30197 - 00100 GPO (P&I Division)Indian Council of Medical Research Nairobi, Post Box 4911, Ansari Nagar, Kenya. New Delhi-110029 India. Dr. Lachhman Das Singla College of Veterinary Science Dr. Ramasamy Harikrishnan Guru Angad Dev Veterinary and Animal Sciences Faculty of Marine Science, College of Ocean University Sciences Ludhiana-141004 Jeju National University Punjab Jeju city, Jeju 690 756 India. South Korea. Editorial Board Dr. Imna Issa Malele Dr. James Culvin Morris Tsetse & Trypanosomiasis Research Institute Clemson
  • Madridge Journal of Immunology

    Madridge Journal of Immunology

    ISSN: 2638-2024 Madridge Journal of Immunology Research Article Open Access Counterproductive contributions to African Epidemiology Helen Lauer1* and Joan Shenton2 1Professor, University of Dar es Salaam, Tanzania 2Director, Meditel Productions, UK Article Info Abstract *Corresponding author: Throughout this retrospective, our purpose is to illuminate an evident knowledge Helen Lauer handicap, cutting across the diagnostic procedures, reportage and mathematical Professor University of Dar es Salaam modelling of chronic illness affecting African public health demographics, which we Dar es Salaam trace to three epistemic injustices (methodological, documental, and professional) in Tanzania the way medical research in Africa is managed and monitored by foreigners. We E-mail: [email protected] propose that the mutual reinforcement of these three different kinds of epistemic transgression underlies the chronic failure of immunologists and public health Received: November 14, 2017 Accepted: November 17, 2017 practitioners to subdue the inflated rates of morbidity and short life expectancy Published: November 24, 2017 persistent throughout Africa. Substandard data collection and implausible infection modelling count as injustices because they are traceable to a routine disregard for best Citation: Lauer H, Shenton J. Counterproductive scientific practice at the upper echelons of global health authority, which is betrayed Madridge contributions to African Epidemiology. by an inordinately high tolerance for diagnostic error concerning populations
  • Taphonomy, Osteometry and Archaeozoology of the Pleistocene Herbivores from the Third Horizon of the Goyet Cave, Belgium

    Taphonomy, Osteometry and Archaeozoology of the Pleistocene Herbivores from the Third Horizon of the Goyet Cave, Belgium

    FACULTEIT WETENSCHAPPEN Opleiding Master in de Geologie Taphonomy, osteometry and archaeozoology of the Pleistocene herbivores from the third horizon of the Goyet cave, Belgium Alexander Comeyne Academiejaar 2012–2013 Scriptie voorgelegd tot het behalen van de graad Van Master of Science in de geologie Promotor: Prof. Dr. J. Verniers Co-promotor: Dr. M. Germonpré Leescommissie: Prof. Dr. Dominique Adriaens, Prof. Dr. Achilles Gautier Acknowledgements Prof. Dr. J. Verniers For proposing this M.Sc. thesis subject and introduction to the Royal Belgian Institute of Natural Sciences Dr. M. Germonpré For reading and contructively criticising the manuscript and answering my questions, as well as support in the practical research . Wilfried Miseur Fot taking photographs of selected specimens RBINS For the opportunity to work with its Goyet collection Summary 1 Introduction .......................................................................................................................................... 3 1.1 Localisation .................................................................................................................................... 5 1.2 Stratigraphy and archaeology ....................................................................................................... 7 1.3 Spatial distribution of Chamber A, Horizon 3 .............................................................................. 10 1.4 Herbivore species .......................................................................................................................
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
  • Parathormone Determination in the Clinical Laboratory: Biochemical, Analytical and Clinical Aspects

    Parathormone Determination in the Clinical Laboratory: Biochemical, Analytical and Clinical Aspects

    UNIVERSITY OF LIEGE FACULTY OF MEDICINE DEPARTMENT OF CLINICAL CHEMISTRY Professor J.P. Chapelle PARATHORMONE DETERMINATION IN THE CLINICAL LABORATORY: BIOCHEMICAL, ANALYTICAL AND CLINICAL ASPECTS. Thesis submitted by Etienne CAVALIER for the degree of « Docteur en Sciences Biomédicales et Pharmaceutiques » Academic year 2009-2010 UNIVERSITY OF LIEGE FACULTY OF MEDICINE DEPARTMENT OF CLINICAL CHEMISTRY Professor J.P. Chapelle PARATHORMONE DETERMINATION IN THE CLINICAL LABORATORY: BIOCHEMICAL, ANALYTICAL AND CLINICAL ASPECTS. Thesis submitted by Etienne CAVALIER for the degree of « Docteur en Sciences Biomédicales et Pharmaceutiques » Academic year 2009-2010 1 University of Liege – Faculty of Medicine Department of Clinical Chemistry. Parathormone determination in the Clinical Laboratory: biochemical, analytical and clinical aspects. Abstract. The aim of our work was to provide comprehensive data to the study of the Parathyroid hormone (Parathormone, or PTH). The first part of the manuscript concerns the “laboratory” aspects of PTH determination. We thus studied the stability of the peptide when stored at different temperatures (pre-analytical phase). From an analytical point of view, we compared different methods for PTH determination and the impact of any change in PTH determination for the follow-up of the hemodialyzed patients. We also studied some analytical interferences and provided a validation strategy that takes into consideration these interferences. Finally, for the post-analytical phase, we established the reference range of PTH with two different methods. We provided guidelines which could help laboratories to establish their own reference range for PTH and studied the clinical impact of applying this newly established reference range in the daily routine. The second part of the manuscript is more dedicated to the “clinical” aspects of PTH determination.